PharmaSUG 2016 Paper IB10
|
|
|
- Griffin Boyd
- 9 years ago
- Views:
Transcription
1 ABSTRACT PharmaSUG 2016 Paper IB10 Moving from Data Collection to Data Visualization and Analytics: Leveraging CDISC SDTM Standards to Support Data Marts Steve Kirby, JD, MS, Chiltern, King of Prussia, Pennsylvania Terek Peterson, MBA, Chiltern, King of Prussia, Pennsylvania Data from clinical trials supports a wide range of clinical, safety, regulatory, and analytic groups who all share the same basic need: to efficiently access, analyze and review the data. When clinical data from multiple studies are combined into a "data mart" and linked to visualization and analytical tools, data consumers are able to efficiently find the information they need to make informed decisions. The raw data as collected in individual studies will vary (at a minimum) based on the specific collection system and forms used. Due to that variability, a foundational step in creating a data mart is to ensure that the data from across studies has a consistent, standard format. We will share our experience leveraging CDISC SDTM standards to support data marts containing data from many studies across several therapeutic areas. Practical considerations related to ensuring 1) that the SDTM implementation is consistent across studies, 2) that the data made available will support all consumer needs, and 3) that the data will be made available as needed by the consumers will be discussed. Thoughts on how the industry shift towards integrating CDASH standards into collection forms will benefit the future state of visualizations and analytics based on data marts will be shared. INTRODUCTION Standardizing study data makes the data more useful. Data that are standardized are easier to understand, analyze, review, and synthesize in an integrated manner in a single study or multiple studies, thereby enabling more effective... decisions. Standardized data also facilitate data exchange and sharing (e.g., between a contract research organization and a sponsor). [Guidance for Industry Providing Regulatory Submissions in Electronic Format Standardized Study Data, Draft, February 2012]. Clinical research is driven by data. Data from clinical trials supports a wide range of clinical, safety, regulatory, and analytic groups who all share the same basic need: to efficiently access, analyze and review the data. That common need has increasingly led to efforts to leverage data from clinical studies using visualization and analytical tools that supply simple and powerful access to pooled study data. DATA MART BASICS AND BENEFITS For the purpose of this paper, a data mart is a database that integrates standardized data from clinical trials across studies and therapeutic areas for a single company. When clinical data from multiple studies are combined and linked to visualization and analytical tools, data consumers are able to efficiently find the information they need to make informed decisions. With proper planning, study data can be effectively integrated from completed studies and (in real time or near real time) from ongoing studies. Raw data are standardized for individual studies, with the standardization done consistently across all studies. After standardization, the data are pooled with data from other studies in the data mart. A simple representation of the concept is in Figure 1 on the next page.
2 Figure 1. Simple Representation of Data Mart Creation With standardized study data, or put another way, stable inputs, analytical and graphical tools can be built, used and reused. With those tools in place, consumers can zoom in or out within and across studies, sites and subjects to detect patterns and signals that are hidden from view in a traditional data environment. Such easy, powerful access can simplify study monitoring, streamline review tasks, guide scientific decisions and support a variety of business needs. DATA STREAM PLANNING The raw data as collected in individual studies will vary (at a minimum) based on the specific collection system and forms used. Due to that variability, a foundational step in creating a data mart is to ensure that the data from across studies has a consistent, standard format. The initial decision is whether to use CDISC SDTM as the basis for standardization for the data mart or to follow a custom standardization strategy. If SDTM is not used as the basis for data mart standardization, there will need to be two data streams (as shown below): one for the data mart, and one for submission as shown in Figure 2 below. Figure 2. Custom and SDTM Standardization, Two Data Streams Using a custom approach (not based on SDTM) for the data mart may allow more flexibility to meet the needs of data mart consumers; and having separate streams for the data mart and for submission, analysis and reporting can avoid planning and coordination issues associated with having the same mapping serve two different consumer groups. Using CDISC SDTM as the basis of standardization for both the data mart and (as needed/required) for analysis, reporting and submission, only one data stream is needed. A simple representation of that is in Figure 3 on the next page.
3 Figure 3. Standardization Based Only on SDTM, One Data Stream With a single data stream based on SDTM feeding both the data mart and submission, analysis and reporting, data standardization is only done once, the data used by each consumer group is the same, the standardization tends to be more complete and comprehensive as the common reference is a global, comprehensive standard, and the cost tends to be lower (doing the work once is cheaper than doing it twice). The single data stream approach is the most common (and increasingly popular) approach. When the data needed for the data mart and for analysis and submission are identical the data stream is clean, simple and most easily managed. We will assume a single data stream based on SDTM for the rest of this paper, and will share a few implementation details where indicated in response to common data consumer needs that make it so the data needed for the data mart contains more content than will be used for analysis and submission. SCOPE OF INPUTS FOR DATA MART BASICS AND BENEFITS What data consumers need from a data mart and for analysis and submission often differ, so it is important to fully understand the needs of all the consumer groups before determining how best to meet them. Analysis and submission needs are more consistent; the SDTM data needs to fully reflect the conduct of the study. If data mart consumers plan to use the data for data review, or to otherwise assess the quality of the collected data, more information likely will be needed for the data mart than for submission. For example, ecrf system variables may be needed to establish a clear link back to the collection forms but would not be included in the submission data; or differently formatted versions of variables maybe be needed to facilitate use. When the data mart needs to contain more information than will be included for submission (when the data mart needs to contain SDTM plus other content as needed for internal data review and evaluation, content in addition to that in the domains and supplemental domains) those needs must to be built into the standardization process. That additional plus information can be added after the SDTM data for submission is generated or the SDTM plus data can be generated as an initial step. Both approaches ensure that the SDTM content used for the data mart and for submission and analysis are consistent, and which is chosen tends to be driven by what fits best based on local needs and preferences. When SDTM plus as needed for the data mart is is created on the backend following creation of SDTM as needed for analysis and submission, the SDTM data mapping processes can be done and maintained just as they would be if serving the data mart was not part of the mix. This tends to make it so SDTM data are available to support analysis needs as quickly as possible and supports a clean, simple path from collection to analysis and submission as shown in figure 4 on the next page.
4 Figure 4. SDTM Standardization, SDTM Plus Created after SDTM But as part of maintaining a clean, simple path to analysis and submission the path to the data mart becomes more complex. This complexity largely is due to the fact that with this approach the SDTM plus input data is SDTM as needed for analysis and submission as opposed to the raw data as collected. Finding a simple, robust way to merge additional raw data content with SDTM can be challenging and careful planning is needed to avoid awkward complications. In some circumstances, content available in the raw data would be mapped for consistency with SDTM and then the mapped back again to have the data as needed for the data mart, in effect duplicating the risk and burden of mapping. Additionally, some of the content needed for the data mart will live in supplemental domains. That supplemental content would only be included in SDTM for submission and analysis when present which can make supporting null variables and providing a consistent input structure for use in the data mart challenging. When SDTM plus as needed for the data mart is created as an initial step, the path to the data mart is streamlined and versatile. To generate SDTM as needed for analysis and submission, the SDTM plus data would be subset and content placed in supplemental domains as needed. This approach is shown in Figure 5 below. Figure 5. SDTM Standardization, SDTM Plus Created before SDTM With this approach the needs of data mart consumers can be most easily met as the data mart inputs are one mapping step away from the data as collected. Information that will eventually live in supplemental domains can be retained even if all values are null. But with that prioritization comes an additional burden as delays in finalization of SDTM plus can affect analysis deliverables, and SDTM plus must contain a complete, compliant set of SDTM content. SCOPE OF INPUTS Many different data consumer groups are likely to leverage a data mart when it is up and running. Understanding what they need and want to evaluate using standardized, pooled data is an important planning step. And the best way to understand their needs is to ask. Reach out the data consumers early and find out whether they need access to both ongoing and completed studies; see if they expect to look at data quality, safety, demographics, compliance, all of the above or all that and more. And while the potential uses of standardized pooled data are almost limitless, resources tend not to be, and understanding which needs are most critical can help establish priorities.
5 Once the planned uses are established, making sure that everyone is on the same page for exactly what content needs to be delivered to support those uses is time well spent. Different groups tend to categorize data differently and translation issues are a risk that needs to be managed. For example, if the stated goal is to evaluate safety, ask specifically what substantive areas are considered to be related to evaluation of safety across studies and how any study specific will additions be documented. Then, once the substantive content is clearly delineated, a clear, shared understanding of where and how it will live in SDTM is typically needed. DATA DELIVERY AND ACCESS Another key part of planning to support a data mart is to ensure that content will be made available to consumers as needed. Often how soon and how often the data need to be delivered is driven by how consumers plan to use it. As an example, if a key use is to assist with data cleaning or to evaluate compliance in ongoing studies, study data will likely need to be available in the data mart soon after the start of study conduct and will need to be refreshed frequently (perhaps nightly). A transfer schedule that starts soon after conduct will tend to be more costly, so it is reasonable to make sure that the cost of expediting the schedule is covered by the benefits. Refreshing standardized data nightly is a different challenge than monthly; having mapping code (or transformations) in place very soon after the start of study conduct is a different challenge than waiting until all data from several subjects are available. Understanding the data delivery schedule early makes it so planning to can comfortably be in place to meet that schedule. Without that planning, timelines will likely to be missed. For example, delivery of SDTM very soon after the start of conduct (even when the collection format is not stable across studies) is manageable with a plan in place to leverage dummy data; without that planning, it likely will not happen. As well, there can be many practical challenges associated with where the data will live, how it will get to its home and who can visit it. The data must be housed in a secure environment with controlled access. The standardized data may be provided by multiple vendors, and applications used to leverage the data mart need to be developed, updated and maintained. A clear, scalable plan to move, house and access the data is needed for the benefits of a data mart to be realized. PLANNING TO CONSISTENTLY IMPLEMENT SDTM A data mart will not work unless that data that feeds it is consistently standardized. The raw data as collected in individual studies will vary (at a minimum) based on the specific collection system and forms used. So a critical part of planning to support a data mart is to have a plan in place to consistently implement SDTM. Reasonable minds can differ at the margins about how to map content into SDTM. Collection standards are often not written consistently across studies and therapeutic areas; and they typically do not match up with CDISC standards as well as they should. One way to effectively manage those standardization challenges is to establish (and maintain) local mapping rules. An effective way to do that is by creating and supporting a local SDTM interpretation guide. The key part of a local SDTM IG is to establish guidelines for how mapping is to be completed. Figure 6 on the next page shows a simple example of that content. These guides can be used by employees and can be provided to multiple vendors to help ensure the SDTM implementation is consistent regardless of who is providing the resources. Additional detail can be added to the guide where useful and manageable in your local environment. From there it is often useful to add additional context by showing exactly how mapping would be done pursuant to the local IG using a representative study.
6 Figure 6. Local SDTM Interpretation Guide (IG) As a first approximation, all raw content that can be standardized should be. Local rules tend to be most critical where CDISC does not specify all (or nearly all) the details. For example, without local rules: One ARMCD may be associated with multiple drugs; one QNAM may have many labels (and meanings); unscheduled visits may be grouped together in some studies, slotted between visits in others. It is also worth mentioning that standards implementation is a process and not an event. Over time inputs vary, CDISC standards evolve and local standards need to be maintained. The acronym G.A.I.N is a concise way to highlight the components of a good standards implementation process. Gather the Information: Listen, understand and develop goals; evaluate current processes; develop a plan for the best approach. Adopt the plan: Leverage in-house and industry knowledge to create Local SDTM IG; draft and review documentation; build and test the standard; schedule regular review meetings Implement the plan: Confirm buy in across all roles/levels of organization so enforcement and transition of standards is successful; provide training. Nurture/Maintain the Standards: Periodic review ensures standards meet business requirements; create processes/documents to support change requirements. SUPPORTING SDTM (AND DATA MARTS) WITH CDASH Best to just say it out loud: SDTM-friendly protocols and CDASH ecrfs make SDTM standardization safer, faster, cheaper, and, well, just better. There is less manipulation of source information, a clearer path from collection to submission and a reduced need for supplemental domains. And with greater harmony between the raw data and SDTM, the data as-collected becomes much closer to SDTM plus, and the data stream needed to serve the data mart needs of many data consumers becomes even more linear as shown in Figure 7 on the next page.
7 Figure 7. SDTM standardization with CDASH One of the most effective strategies to support a data mart is to work (with CDASH) to collect what you submit. If CDASH conventions are followed (where applicable) for each variable collected on an ecrf, many variables will directly map into SDTM, and conversion to SDTM can be further simplified by leveraging mapping associations available from CDISC. With support from CDASH collection standards, a local interpretation guide can be generated, supported and used with less effort. DATA MART VISUALIZATION Standardized data are more useful. With data from studies standardized and pooled in a data mart, visualization tools can be efficiently created then used and reused. Many different types of data consumers can view and review the data using accessible user interfaces. Figure 8 below shows a couple simple, useful graphs that were created based on standardized data. Figure 8. Data Mart Visualization: Example Graphs With data standardized and pooled, and with visualization tools in place, consumers can zoom in or out within and across studies, sites and subjects to detect patterns and signals that are hidden from view in a traditional data environment. Such easy, powerful access can simplify study monitoring, streamline review tasks, guide scientific decisions and support a variety of business needs.
8 CONCLUSION Standardization makes data more useful, and a data mart linked to powerful visualization and analytical tools is a great way to help all the data consumers in your company see just how useful standardized data can be. Basing data standardization for a data mart on SDTM will often lead to efficiencies as SDTM data are already needed for analysis and submission; and creating (and maintaining) a local SDTM IG is one practical way to ensure that the SDTM data are consistently generated across studies, therapeutic areas and vendors. Planning for SDTM before you collect the data with SDTM-friendly protocols and CDASH ecrfs will further reduce the challenges (and cost) of data standardization. Reach out to the data consumers at your company. Discuss what they need. Then show them how a data mart can help meet those needs. AKNOWLEDGMENTS The authors would like to thank Chiltern International Limited for supporting CDISC standards implementation (and this paper). We would also like to thank the CDISC community. Without the CDISC organization and the time and effort of its many, many volunteers, the data standards we use to streamline the drug discovery process would not exist. REFERENCE FDA, Guidance for Industry Providing Regulatory Submissions in Electronic Format Standardized Study Data [DRAFT]. FDA. FDA.gov. February, Available at: al/ucm pdf CONTACT INFORMATION Your comments and questions are valued and encouraged. Contact the authors at: Name: Steven Kirby, JD, MS Name: Terek Peterson, MBA Enterprise: Chiltern Enterprise: Chiltern Work Phone: Work Phone: (484) [email protected] [email protected] Web: Web: SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. indicates USA registration. Other brand and product names are trademarks of their respective companies.
USE CDISC SDTM AS A DATA MIDDLE-TIER TO STREAMLINE YOUR SAS INFRASTRUCTURE
USE CDISC SDTM AS A DATA MIDDLE-TIER TO STREAMLINE YOUR SAS INFRASTRUCTURE Kalyani Chilukuri, Clinovo, Sunnyvale CA WUSS 2011 Annual Conference October 2011 TABLE OF CONTENTS 1. ABSTRACT... 3 2. INTRODUCTION...
Rationale and vision for E2E data standards: the need for a MDR
E2E data standards, the need for a new generation of metadata repositories Isabelle de Zegher, PAREXEL Informatics, Belgium Alan Cantrell, PAREXEL, United Kingdom Julie James, PAREXEL Informatics, United
Paper DM10 SAS & Clinical Data Repository Karthikeyan Chidambaram
Paper DM10 SAS & Clinical Data Repository Karthikeyan Chidambaram Cognizant Technology Solutions, Newbury Park, CA Clinical Data Repository (CDR) Drug development lifecycle consumes a lot of time, money
BRIDGing CDASH to SAS: How Harmonizing Clinical Trial and Healthcare Standards May Impact SAS Users Clinton W. Brownley, Cupertino, CA
BRIDGing CDASH to SAS: How Harmonizing Clinical Trial and Healthcare Standards May Impact SAS Users Clinton W. Brownley, Cupertino, CA ABSTRACT The Clinical Data Interchange Standards Consortium (CDISC),
A Comparison of Two Commonly Used CRO Resourcing Models for SAS/ Statistical Programmers R. Mouly Satyavarapu, PharmaNet/ i3, Ann Arbor, MI
PharmaSUG 2012 - Paper MS11 A Comparison of Two Commonly Used CRO Resourcing Models for SAS/ R. Mouly Satyavarapu, PharmaNet/ i3, Ann Arbor, MI ABSTRACT: Why do we have Contract Research Organizations
Managing and Integrating Clinical Trial Data: A Challenge for Pharma and their CRO Partners
Managing and Integrating Clinical Trial Data: A Challenge for Pharma and their CRO Partners Within the Pharmaceutical Industry, nothing is more fundamental to business success than bringing drugs and medical
WHITE PAPER. CONVERTING SDTM DATA TO ADaM DATA AND CREATING SUBMISSION READY SAFETY TABLES AND LISTINGS. SUCCESSFUL TRIALS THROUGH PROVEN SOLUTIONS
WHITE PAPER CONVERTING SDTM DATA TO ADaM DATA AND CREATING SUBMISSION READY SAFETY TABLES AND LISTINGS. An innovative approach to deliver statistical analysis and data in a CDISC ADaM complient manner
eclinical Services Predictable Pricing Full Service EDC Phase I-IV Sophisticated Edit Checks Drug Supply Chain Forms Library Data Collection Services
eclinical Services Predictable Pricing Full Service EDC Phase I-IV Sophisticated Edit Checks Data Collection Services Drug Supply Chain Forms Library Real-time Data Access Clinical Data Management Electronic
SDTM AND ADaM: HANDS-ON SOLUTIONS
SDTM AND ADaM: HANDS-ON SOLUTIONS CDISC French Speaking User Group Paris, France 17 February 2012 Joris De Bondt, Head Data Standards & Process Improvements Tineke Callant, Senior Biostatistical Analyst
Using SAS Data Integration Studio to Convert Clinical Trials Data to the CDISC SDTM Standard Barry R. Cohen, Octagon Research Solutions, Wayne, PA
Using SAS Data Integration Studio to Convert Clinical Trials Data to the CDISC SDTM Standard Barry R. Cohen, Octagon Research Solutions, Wayne, PA ABSTRACT A new industry standard for clinical trials data,
PharmaSUG2010 - Paper HS01. CDASH Standards for Medical Device Trials: CRF Analysis. Parag Shiralkar eclinical Solutions, a Division of Eliassen Group
PharmaSUG2010 - Paper HS01 CDASH Standards for Medical Device Trials: CRF Analysis Parag Shiralkar eclinical Solutions, a Division of Eliassen Group Jennie Tedrow Boston Scientific Kit Howard Kestrel Consultants
Accenture Accelerated R&D Services: CDISC Conversion Service Overview
Accenture Life Sciences Rethink Reshape Restructure for better patient outcomes Accenture Accelerated R&D Services: CDISC Conversion Service Overview Using standards to drive speed to market and meet regulatory
Automate Data Integration Processes for Pharmaceutical Data Warehouse
Paper AD01 Automate Data Integration Processes for Pharmaceutical Data Warehouse Sandy Lei, Johnson & Johnson Pharmaceutical Research and Development, L.L.C, Titusville, NJ Kwang-Shi Shu, Johnson & Johnson
PharmaSUG2010 HW06. Insights into ADaM. Matthew Becker, PharmaNet, Cary, NC, United States
PharmaSUG2010 HW06 Insights into ADaM Matthew Becker, PharmaNet, Cary, NC, United States ABSTRACT ADaM (Analysis Dataset Model) is meant to describe the data attributes such as structure, content, and
PharmaSUG 2013 - Paper IB05
PharmaSUG 2013 - Paper IB05 The Value of an Advanced Degree in Statistics as a Clinical Statistical SAS Programmer Mark Matthews, inventiv Health Clinical, Indianapolis, IN Ying (Evelyn) Guo, PAREXEL International,
ADaM Implications from the CDER Data Standards Common Issues and SDTM Amendment 1 Documents Sandra Minjoe, Octagon Research Solutions, Wayne, PA
ABSTRACT: ADaM Implications from the CDER Data Standards Common Issues and SDTM Amendment 1 Documents Sandra Minjoe, Octagon Research Solutions, Wayne, PA Over the past few years, the United States Food
Needs, Providing Solutions
Identifying Needs, Providing Solutions 1 I n d u s t r y The growth of medical research and the countless innovations coming from the pharmaceutical, biotechnology and medical device industry, has improved
ABSTRACT INTRODUCTION THE MAPPING FILE GENERAL INFORMATION
An Excel Framework to Convert Clinical Data to CDISC SDTM Leveraging SAS Technology Ale Gicqueau, Clinovo, Sunnyvale, CA Marc Desgrousilliers, Clinovo, Sunnyvale, CA ABSTRACT CDISC SDTM data is the standard
Clinical Data Management BPaaS Approach HCL Technologies
Leading pharmaceutical companies are estimating new business models including alternative Clinical data management platforms to reduce costs, shorten timelines, and maintain quality and compliance. HCL
OPERATIONALIZING EXCELLENCE IN THE GLOBAL REGULATORY SUBMISSIONS PROCESS
OPERATIONALIZING EXCELLENCE IN THE GLOBAL REGULATORY SUBMISSIONS PROCESS INTRODUCTION As life sciences companies face expiring patents and shrinking drug-development pipelines, it s never been more important
SDTM, ADaM and define.xml with OpenCDISC Matt Becker, PharmaNet/i3, Cary, NC
PharmaSUG 2012 - Paper HW07 SDTM, ADaM and define.xml with OpenCDISC Matt Becker, PharmaNet/i3, Cary, NC ABSTRACT Standards are an ongoing focus of the health care and life science industry. Common terms
UTILIZING CDISC STANDARDS TO DRIVE EFFICIENCIES WITH OPENCLINICA Mark Wheeldon CEO, Formedix Boston June 21, 2013
UTILIZING CDISC STANDARDS TO DRIVE EFFICIENCIES WITH OPENCLINICA Mark Wheeldon CEO, Formedix Boston June 21, 2013 AGENDA Introduction Real World Uses : Saving Time & Money. Your Clinical Trials Automated.
Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management
Written Notice of Participation by the Clinical Data Interchange Standards Consortium (CDISC) and Written Statement for Discussion Topics to be Addressed In the FDA Public Hearing: Electronic Submission
A white paper presented by: Barry Cohen Director, Clinical Data Strategies Octagon Research Solutions, Inc. Wayne, PA
THE CLINICAL DATA AND REGULATORY EXPERTS SDTM, Plus or Minus A white paper presented by: Barry Cohen Director, Clinical Data Strategies Octagon Research Solutions, Inc. Wayne, PA This Whitepaper is for
Statistical Operations: The Other Half of Good Statistical Practice
Integrating science, technology and experienced implementation Statistical Operations: The Other Half of Good Statistical Practice Alan Hopkins, Ph.D. Theravance, Inc. Presented at FDA/Industry Statistics
Graphing Made Easy for Project Management
Paper 7300-2016 Graphing Made Easy for Project Management Zhouming (Victor) Sun, AZ/Medimmune Corp., Gaithersburg, MD ABSTRACT Project management is a hot topic across many industries, and there are multiple
CDISC standards and data management The essential elements for Advanced Review with Electronic Data
Session 6: Toward Electronic Submission of Study Data for New Drug Applications CDISC standards and data management The essential elements for Advanced Review with Electronic Data Yuki Ando Senior Scientist
Adopting Site Quality Management to Optimize Risk-Based Monitoring
Adopting Site Quality Management to Optimize Risk-Based Monitoring Medidata and other marks used herein are trademarks of Medidata Solutions, Inc. All other trademarks are the property of their respective
White Paper. Thirsting for Insight? Quench It With 5 Data Management for Analytics Best Practices.
White Paper Thirsting for Insight? Quench It With 5 Data Management for Analytics Best Practices. Contents Data Management: Why It s So Essential... 1 The Basics of Data Preparation... 1 1: Simplify Access
ClinPlus. Clinical Trial Management System (CTMS) Technology Consulting Outsourcing. Expedite trial design and study set-up
Technology Consulting Outsourcing ClinPlus Clinical Trial Management System (CTMS) Expedite trial design and study set-up Efficiently collect and manage patient and trial administration data Benefit from
PRACTICAL USE CASES BPA-AS-A-SERVICE: The value of BPA
BPA-AS-A-SERVICE: PRACTICAL USE CASES How social collaboration and cloud computing are changing process improvement TABLE OF CONTENTS 1 Introduction 1 The value of BPA 2 Social collaboration 3 Moving to
Clinical Trial Data Integration: The Strategy, Benefits, and Logistics of Integrating Across a Compound
PharmaSUG 2014 - Paper AD21 Clinical Trial Data Integration: The Strategy, Benefits, and Logistics of Integrating Across a Compound ABSTRACT Natalie Reynolds, Eli Lilly and Company, Indianapolis, IN Keith
Medical Data Review and Exploratory Data Analysis using Data Visualization
Paper PP10 Medical Data Review and Exploratory Data Analysis using Data Visualization VINOD KERAI, ROCHE, WELWYN, UKINTRODUCTION Drug Development has drastically changed in the last few decades. There
The 505(b)(2) Drug Development Pathway:
The 505(b)(2) Drug Development Pathway: When and How to Take Advantage of a Unique American Regulatory Pathway By Mukesh Kumar, PhD, RAC and Hemant Jethwani, MS The 505(b)(2) regulation offers a less expensive
PharmaSUG 2015 - Paper DS07
PharmaSUG 2015 - Paper DS07 The Best Practices of CDISC Validation Checks: Past, Present, and Future Shelley Dunn, d-wise, Morrisville, NC Ed Lombardi, Agility Clinical, Carlsbad, CA ABSTRACT The CDISC
Implementation of SDTM in a pharma company with complete outsourcing strategy. Annamaria Muraro Helsinn Healthcare Lugano, Switzerland
Italian-Speaking CDISC User Group 2008 Implementation of SDTM in a pharma company with complete outsourcing strategy Annamaria Muraro Helsinn Healthcare Lugano, Switzerland Background Full outsourcing
Streamlining the drug development lifecycle with Adobe LiveCycle enterprise solutions
White paper Streamlining the drug development lifecycle with Adobe LiveCycle enterprise solutions Using intelligent PDF documents to optimize collaboration, data integrity, authentication, and reuse Table
ABSTRACT INTRODUCTION PATIENT PROFILES SESUG 2012. Paper PH-07
Paper PH-07 Developing a Complete Picture of Patient Safety in Clinical Trials Richard C. Zink, JMP Life Sciences, SAS Institute, Cary, NC, United States Russell D. Wolfinger, JMP Life Sciences, SAS Institute,
The ADaM Solutions to Non-endpoints Analyses
The ADaM Solutions to Non-endpoints Analyses ABSTRACT Chengxin Li, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA There always exist some analyses for non endpoints in the study. These
CDISC Roadmap Outline: Further development and convergence of SDTM, ODM & Co
CDISC Roadmap Outline: Further development and convergence of SDTM, ODM & Co CDISC Ausblick: Weitere Entwicklung und Konvergenz der CDISC-Standards SDTM, ODM & Co. Jozef Aerts - XML4Pharma Disclaimer Views
Organization Profile. IT Services
Introduction In today s scientific and medical world, various issues in clinical trials and research have permeated every society and every field in medicine. Ethics and in particular the quality of research
INSERT COMPANY LOGO HERE BEST PRACTICES RESEARCH
INSERT COMPANY LOGO HERE BEST PRACTICES RESEARCH Background and Company Performance Industry Challenges esource: Electronic Clinical Trial Solution Clinical trial sponsors and clinical research organizations
An Introduction to Electronic Data Capture Software. Learn the basics to find the right system for your needs
An Introduction to Electronic Data Capture Software Learn the basics to find the right system for your needs By Forte Research Systems Software to fit your clinical research needs Cloud-based clinical
Did you know? Accenture can deliver business outcome-focused results for your life sciences research & development organization like these:
How can Accenture Accelerated R&D BPO Services help you achieve greater business value? Did you know? Accenture can deliver business outcome-focused results for your life sciences research & development
CLINICAL DEVELOPMENT OPTIMIZATION
PAREXEL CLINICAL RESEARCH SERVICES CLINICAL DEVELOPMENT OPTIMIZATION Enhancing the clinical development process to achieve optimal results ADVANCED TECHNOLOGY COMBINED WITH INTELLIGENT THINKING CAN HELP
End-to-End E-Clinical Coverage with Oracle Health Sciences InForm GTM
End-to-End E-Clinical Coverage with InForm GTM A Complete Solution for Global Clinical Trials The broad market acceptance of electronic data capture (EDC) technology, coupled with an industry moving toward
DIaaS (Data Integration as A Service) CDISC Conversion Platform
www.hcltech.com DIaaS (Data Integration as A Service) CDISC Conversion Platform HCL DIaaS (Data Integration as A Service) - CDISC Conversion Platform Industry Perspective The majority of commercially available
Paper 064-2014. Robert Bonham, Gregory A. Smith, SAS Institute Inc., Cary NC
Paper 064-2014 Log entries, Events, Performance Measures, and SLAs: Understanding and Managing your SAS Deployment by Leveraging the SAS Environment Manager Data Mart ABSTRACT Robert Bonham, Gregory A.
Business & Decision Life Sciences
Business & Decision Life Sciences Define-it: Demo webinar Anne-Sophie Bekx / 20th May 2014 INSERT COMPANY LOGO IN MASTER SLIDE HERE History of Define.xml Define-it Software Demo Define-it versions Q &
EMC PERSPECTIVE. The Private Cloud for Healthcare Enables Coordinated Patient Care
EMC PERSPECTIVE The Private Cloud for Healthcare Enables Coordinated Patient Care Table of Contents A paradigm shift for Healthcare IT...................................................... 3 Cloud computing
Data Standards in Clinical Trials, A Regulatory Perspec9ve
Data Standards in Clinical Trials, A Regulatory Perspec9ve NIH Data Standards Forum: Maximizing Innova8on by Standardizing Mary Ann Slack Center for Drug Evalua9on and Research (CDER) U.S. Food and Drug
Sanofi-Aventis Experience Submitting SDTM & Janus Compliant Datasets* SDTM Validation Tools - Needs and Requirements
In-Depth Review of Tools to Check Compliance of CDISC - Ready Clinical s Bhavin Busa March 2 nd, 2011 Managing Clinical in the Age of CDISC BASUG Quarterly Meeting Presentation Outline Brief introduction
Overview of CDISC Implementation at PMDA. Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA)
Overview of CDISC Implementation at PMDA Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA) CDISC 2012 Outline Introduction Update of PMDA activity CDISC implementation
Infoset builds software and services to advantage business operations and improve patient s life
Infoset builds software and services to advantage business operations and improve patient s life Clinical Data Management ecrf & EDC Patient Support Programs Medication Adherence Mobile e-health Big Data
Product Lifecycle Management in the Medical Device Industry. An Oracle White Paper Updated January 2008
Product Lifecycle Management in the Medical Device Industry An Oracle White Paper Updated January 2008 Product Lifecycle Management in the Medical Device Industry PLM technology ensures FDA compliance
Development of CDISC Tuberculosis Data Standards
Development of CDISC Tuberculosis Data Standards Michael Fiola Senior Director / Quintiles The presenters have disclosed that they have no proprietary or financial interests in the topics covered in this
ORACLE AGILE PLM FOR THE MEDICAL DEVICE INDUSTRY
ORACLE AGILE PLM FOR THE MEDICAL DEVICE INDUSTRY Enterprise PLM is a strategic approach to managing the lifecycle of a product throughout its full value chain: from initial requirements gathering through
Introduction to the CDISC Standards
Introduction to the CDISC Standards Sandra Minjoe, Accenture Life Sciences, Wayne, Pennsylvania ABSTRACT The Clinical Data Interchange Standards Consortium (CDISC) encompasses a suite of standards across
QLIKVIEW FOR LIFE SCIENCES. Partnering for Innovation and Sustainable Growth
QLIKVIEW FOR LIFE SCIENCES Partnering for Innovation and Sustainable Growth A BUSINESS MODEL BUILT FOR INSIGHT Success in today s life sciences industry requires insight into volumes of data, the sharing
Practical application of SAS Clinical Data Integration Server for conversion to SDTM data
Paper DM03 Practical application of SAS Clinical Data Integration Server for conversion to SDTM data Peter Van Reusel, Business & Decision Life Sciences, Brussels, Belgium Mark Lambrecht, SAS, Tervuren,
Web Analytics Understand your web visitors without web logs or page tags and keep all your data inside your firewall.
Web Analytics Understand your web visitors without web logs or page tags and keep all your data inside your firewall. 5401 Butler Street, Suite 200 Pittsburgh, PA 15201 +1 (412) 408 3167 www.metronomelabs.com
Transforming CliniCal Trials: The ability to aggregate and Visualize Data Efficiently to make impactful Decisions
: The ability to aggregate and Visualize Data Efficiently to make impactful Decisions www.eclinicalsol.com White Paper Table of Contents Maximizing Your EDC Investment... 3 Emerging Trends in Data Collection...
Lessons Learned from the QC Process in Outsourcing Model Faye Yeh, Takeda Development Center Americas, Inc., Deerfield, IL
ABSTRACT PharmaSUG 2015 Paper TT11 Lessons Learned from the QC Process in Outsourcing Model Faye Yeh, Takeda Development Center Americas, Inc., Deerfield, IL As more and more companies in the pharmaceutical
Empowering Global Medical Information Teams with Software Solutions
www.arisglobal.com A White Paper Presented By ArisGlobal Empowering Global Medical Information Teams with Software Solutions by Ome Ogbru, PharmD, Medical Information, SME Empowering Global Medical Information
Building and Customizing a CDISC Compliance and Data Quality Application Wayne Zhong, Accretion Softworks, Chester Springs, PA
WUSS2015 Paper 84 Building and Customizing a CDISC Compliance and Data Quality Application Wayne Zhong, Accretion Softworks, Chester Springs, PA ABSTRACT Creating your own SAS application to perform CDISC
Bringing Order to Your Clinical Data Making it Manageable and Meaningful
CLINICAL DATA MANAGEMENT Bringing Order to Your Clinical Data Making it Manageable and Meaningful eclinicalsol.com DATA IS SIMPLY BEAUTIFUL DATA STACKS IN STANDARD FORMATION This imaginative visual suggests
Big Data Integration: A Buyer's Guide
SEPTEMBER 2013 Buyer s Guide to Big Data Integration Sponsored by Contents Introduction 1 Challenges of Big Data Integration: New and Old 1 What You Need for Big Data Integration 3 Preferred Technology
An information platform that delivers clinical studies better, faster, safer and more cost effectively
An information platform that delivers clinical studies better, faster, safer and more cost effectively Powering Process & Performance Proactively manage study start-up and execution Risk profile new sites
Clinical Data Management Overview
The 2 nd Clinical Data Management Training Clinical Data Management Overview Andrew Taylor ( 安 泰 乐 ), M.S. Head of Clinical Data Management August 30, 2010 Learning Objectives Overview of Process Related
Use of Metadata to Automate Data Flow and Reporting. Gregory Steffens Novartis PhUSE 13 June 2012
Use of Metadata to Automate Data Flow and Reporting Gregory Steffens Novartis PhUSE 13 June 2012 Stages of Metadata Evolution I In the beginning... No corporate or industry level data or reporting standards
The Development of the Clinical Trial Ontology to standardize dissemination of clinical trial data. Ravi Shankar
The Development of the Clinical Trial Ontology to standardize dissemination of clinical trial data Ravi Shankar Open access to clinical trials data advances open science Broad open access to entire clinical
The Power of Personalizing the Customer Experience
The Power of Personalizing the Customer Experience Creating a Relevant Customer Experience from Real-Time, Cross-Channel Interaction WHITE PAPER SAS White Paper Table of Contents The Marketplace Today....1
Understanding CDISC Basics
Trends in Bio/Pharmaceutical Industry Understanding CDISC Basics Jane Ma Abstract Data standards can make data and its associated program more portable. The CDISC (Clinical Data Interchange Standards Consortium)
Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools
Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools Laura McKain, M.D., Medical Director, Pharmacovigilance; Tammy Jackson, Director, Preclarus Development, Clinical Innovation;
The Evolution of Data Management Job Models. in the Execution of Clinical Trials. [email protected]. www.kcrcro.com
The Evolution of Data Management Job Models in the Execution of Clinical Trials [email protected] KCR S.A. Corporate Headquarters 6 Postepu str., 02-676 Warsaw Phone: +48 22 313 13 13 Fax: +48 22 313 13 14
SAS Drug Development User Connections Conference 23-24Jan08
SAS Drug Development User Connections Conference 23-24Jan08 Bernd Doetzkies David Ramage Daiichi Sankyo Pharma Development DSPD Clinical Data Repository System Business Drivers System Overview People and
Five Tenets of Modern Procurement Move Source-to-Pay to the Cloud
ENTERPRISE RESOURCE PLANNING CLOUD Five Tenets of Modern Procurement Move Source-to-Pay to the Cloud Copyright 2014 Oracle Corporation. All Rights Reserved. Modern procurement organizations are continually
Lessons on the Metadata Approach. Dave Iberson- Hurst 9 th April 2014 CDISC Euro Interchange 2014
1 Lessons on the Metadata Approach Dave Iberson- Hurst 9 th April 2014 CDISC Euro Interchange 2014 2 Experience Human beings, who are almost unique in having the ability to learn from the experience of
PharmaSUG 2014 - Paper PO01
ABSTRACT PharmaSUG 2014 - Paper PO01 A User Friendly Tool to Facilitate the Data Integration Process Yang Wang, Seattle Genetics, Inc., Bothell, WA Boxun Zhang, Seattle Genetics, Inc., Bothell, WA For
Digging for Gold: Business Usage for Data Mining Kim Foster, CoreTech Consulting Group, Inc., King of Prussia, PA
Digging for Gold: Business Usage for Data Mining Kim Foster, CoreTech Consulting Group, Inc., King of Prussia, PA ABSTRACT Current trends in data mining allow the business community to take advantage of
ClinPlus. Report. Technology Consulting Outsourcing. Create high-quality statistical tables and listings. An industry-proven authoring tool
Technology Consulting Outsourcing ClinPlus Report Create high-quality statistical tables and listings An industry-proven authoring tool Ensure consistency across different programmers Extensive Template
ORACLE CLINICAL. Globalization. Flexibility. Efficiency. Competition ORACLE DATA SHEET OVERVIEW ROBUST CLINICAL DATA MANAGEMENT SOLUTION
ORACLE CLINICAL OVERVIEW ROBUST CLINICAL DATA MANAGEMENT SOLUTION Smoothly transition from paper to EDC trials Annotated CRFs provides an intuitive means of creating submission-ready annotations Improved
The Future of Census Bureau Operations
The Future of Census Bureau Operations Version 1.0 April 25, 2013 The Future of Census Bureau Operations Page ii [This page intentionally left blank] The Future of Census Bureau Operations Page iii Document
Monitoring Clinical Trials with a SAS Risk-Based Approach
Paper DH05 Monitoring Clinical Trials with a SAS Risk-Based Approach Laurie Rose, SAS, Cary, NC USA ABSTRACT With global regulatory encouragement, the life sciences industry is gaining momentum to embrace
Gregory S. Nelson ThotWave Technologies, Cary, North Carolina
Using SAS 9 in Clinical Research Gregory S. Nelson ThotWave Technologies, Cary, North Carolina Abstract For 30 years SAS has been used in pharmaceutical research settings for data management, analytics
See What's Coming in Oracle Project Portfolio Management Cloud
See What's Coming in Oracle Project Portfolio Management Cloud Release 9 Release Content Document Table of Contents GRANTS MANAGEMENT... 4 Collaborate Socially on Awards Using Oracle Social Network...
ADaM or SDTM? A Comparison of Pooling Strategies for Integrated Analyses in the Age of CDISC
Paper CD01 ADaM or SDTM? A Comparison of Pooling Strategies for Integrated Analyses in the Age of CDISC Joerg Guettner, Bayer Pharma AG, Wuppertal, Germany Alexandru Cuza, UCB Biosciences GmbH, Monheim,
PharmaSUG2010 - Paper CD13
PharmaSUG2010 - Paper CD13 In-Depth Review of Validation Tools to Check Compliance of CDISC SDTM-Ready Clinical Datasets Bhavin Busa, Cubist Pharmaceuticals, Inc., Lexington, MA Kim Lindfield, Cubist Pharmaceuticals,
Streamlining the Flow of Clinical Trial Data: EHR to EDC to Sponsor
Streamlining the Flow of Clinical Trial : EHR to EDC to Sponsor Landen Bain Liaison to Healthcare CDISC Interchange Standards Consortium) Jane Griffin, RPh Director, Pharmaceutical Research Cerner Corporation
Extracting and Preparing Metadata to Make Video Files Searchable
Extracting and Preparing Metadata to Make Video Files Searchable Meeting the Unique File Format and Delivery Requirements of Content Aggregators and Distributors Table of Contents Executive Overview...
4. Executive Summary of Part 1 FDA Overview of Current Environment
Public Meeting Regulatory New Drug Review: Solutions for Study Data Exchange Standards 1. Background Meeting Summary Food and Drug Administration White Oak, MD November 5, 2012 10am 4pm On November 5,
Handbook for finding the right FX Broker
Handbook for finding the right FX Broker With currency trading becoming even more popular, the number of brokers is growing at a rapid rate. What should one look at when deciding which broker to open an
